Latest filing published 30 Oct 2026 for Immunovant, Inc., €169k.
Filing timeline
BuySaleInsider track record
Closed purchases
Based on 3 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- -61.6%Entry US$1,068,750.00 · Close at T+365 US$410,625.00
- -16.3%Entry US$1,209,375.00 · Close at T+365 US$1,012,500.00
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Tiago Girao: trading record in brief
Filings by Tiago Girao span 2 companies, the busiest being Immunovant, Inc. and Cerenome, Inc. We count 13 filings; the first trade dates from 11 November 2014 and the latest from 28 October 2026.
On the open market, the record shows 3 purchases worth €28k and 4 sales worth €1.4M. The net balance comes to €1.4M on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Besides market trades, the filings include 5 share grants and 1 option exercise. So far in 2026, the count stands at no purchases and 4 sales.
A typical purchase (the median) is worth €8,839. Looking at 3 purchases old enough to measure, the stock rose over the following 90 days in 67% of cases; the median change was +9.3%. Past outcomes like these are no guarantee of what comes next.
Most recently, on 30 October 2026, the filings show an open-market sale worth €169k in Immunovant, Inc. The latest purchase dates back some time: it was published 4,100 days ago, on 19 August 2015. Typically, a trade is published a median of 1 day after it takes place. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Tiago Girao
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 6,606 shares@ US$28.50Common StockSEC:0001764013-26-000117:0
- 6,798 shares@ US$38.690.0037% mcap26.1% of flowCommon StockSEC:0001618670-26-000004:0
- 10,000 shares@ US$38.4627.7% of flowCommon StockSEC:0001764013-26-000072:1
- 10,000 sharesCommon StockSEC:0001764013-26-000072:0
- 25,760 shares@ US$29.620.0082% mcap73.9% of flowCommon StockSEC:0001764013-26-000056:0
- 64,968 shares0Common StockSEC:0001764013-26-000032:0
- 208,388 shares0Common StockSEC:0001415889-25-012047:0
- 5,667 sharesCommon StockSEC:0001140361-16-069911:0
- 35,250 sharesCommon StockSEC:0001140361-16-050458:0
- 35,250 sharesCommon StockSEC:0001140361-16-049631:0
- 25,000 shares@ US$0.39Common StockSEC:0001140361-15-032810:0Canonical exit: 16 Nov 2015 (T+90)
- 15,889 shares@ US$0.39Common StockSEC:0001140361-14-041402:0Canonical exit: 9 Feb 2015 (T+90)
- 44,111 shares@ US$0.39Common StockSEC:0001140361-14-041402:1Canonical exit: 10 Feb 2015 (T+90)
13 of 13 declarations
